Tarsus Pharmaceuticals, Inc. TARS Unamortized Discount and Issuance Costs
Unamortized Discount and Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs?
- Tarsus Pharmaceuticals, Inc. (TARS) reported unamortized discount and issuance costs of $3.52M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs decreased by 0.0% year-over-year, from $3.52M to $3.52M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs?
- Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s unamortized discount and issuance costs has grown at a 59.1% compound annual growth rate (CAGR), from $875K to $3.52M.
- What does unamortized discount and issuance costs mean?
- This represents the portion of debt issuance costs and original issue discounts that have not yet been recognized as interest expense on the income statement. It serves as a contra-liability account that reduces the carrying value of debt on the balance sheet. Tracking this is critical for understanding the true effective interest rate and the total cost of capital over the life of the debt instruments.